Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

EDAP's Focal One® Robotic HIFU Treatments Performed at Acibadem Hospital, Istanbul, Turkey

Posted on: 18 Dec 17


LYON, France, December 18, 2017 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced the first HIFU treatments performed at Acibadem Hospital, Istanbul, Turkey, using the Company's Focal One Robotic HIFU device.  

Prof. Ali Riza Kural, Head of Urology Department and Prof. Can Obek at Acibadem Hospital, commented: "We are very excited to be the first Healthcare center in Turkey to offer the innovative HIFU technology; we successfully treated seven patients with prostate cancer using the Focal One HIFU device. Acibadem Hospital is the leading center in Turkey for the treatment of prostate cancer, by complementing our existing therapeutic solutions with the Focal One HIFU device, Acibadem maintains its leadership in providing new, innovative urology techniques and developments to its patients."

Marc Oczachowski, EDAP TMS Chief Executive Officer, added: "We are very proud to announce the first Focal One cases done in Istanbul at the prestigious private Acibadem Hospital. With Professor Kural's world-class Urology team, Acibadem Healthcare Group will soon become a HIFU center of excellence in Turkey and in the region. This new installation is a key achievement for both EDAP TMS and its exclusive distributor ANDROMED, in offering EDAP's unique, innovative Focal One technology to patients with prostate cancer in Turkey as well as the Middle East."


EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved for commercial distribution in Europe and some other countries including Mexico and Canada, and has received 510(k) clearance by the U.S. FDA. Ablatherm Fusion also is FDA cleared. The Company also markets an innovative robot-assisted HIFU device, the Focal One®, dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith® lithotripters' range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visit , and

About Acibadem Healthcare Group

The Acibadem Healthcare Group, whose first hospital was established in 1991, is Turkey's most valuable private healthcare organisation according to brand assessment results and the position the group has achieved in the sector. Today the Acibadem Healthcare Group, with its 21 hospitals, 16 outpatient clinics, 3.500 doctors and 4.000 nurses, provides healthcare services with nearly 22.500 employees. The Group provides diagnosis and treatment services at certified healthcare standards with a qualified staff, advanced technology, modern infrastructure and JCI accreditation. Today Acibadem cannot be defined simply as an institution providing diagnosis and treatment services. In addition to its hospitals and outpatient clinics, the Acibadem Healthcare Group has support service companies with which it provides "360-degree" service in every field of medicine. Continuing to serve with a specially developed integrated model, Acibadem has created a special ecosystem in healthcare. For more information on Acibadem Healthcare Group, please visit:

Company Contact

Blandine Confort

Investor Relations / Legal Affairs


+33 4 72 15 31 72

Investor Contact

Rich Cockrell

CG Capital


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: EDAP TMS SA via GlobeNewswire

Last updated on: 19/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.